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ABSTRACT
Objective: To evaluate the effects of oral delayed-release dimethyl fumarate (DMF; also known as
gastro-resistant DMF) on MRI lesion activity and load, atrophy, and magnetization transfer ratio
(MTR) measures from the Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Scle-
rosis (CONFIRM) study.
Methods: CONFIRMwas a 2-year, placebo-controlled study of the efficacy and safety of DMF240mg
twice (BID) or 3 times daily (TID) in 1,417 patients with relapsing-remitting multiple sclerosis (RRMS);
subcutaneous glatiramer acetate 20 mg once daily was included as an active reference comparator.
The number and volume of T2-hyperintense, T1-hypointense, and gadolinium-enhancing (Gd1) lesions,
as well as whole brain volume and MTR, were assessed in 681 patients (MRI cohort).
Results: DMF BID and TID produced significant and consistent reductions vs placebo in the num-
ber of new or enlarging T2-hyperintense lesions and new nonenhancing T1-hypointense lesions
after 1 and 2 years of treatment and in the number of Gd1 lesions at week 24, year 1, and year
2. Lesion volumes were also significantly reduced. Reductions in brain atrophy and MTR changes
with DMF relative to placebo did not reach statistical significance.
Conclusions: The robust effects on MRI active lesion counts and total lesion volume in patients with
RRMS demonstrate the ability of DMF to exert beneficial effects on inflammatory lesion activity in mul-
tiple sclerosis, and support DMF therapy as a valuable new treatment option in RRMS.
Classification of evidence: This study provides Class I evidence of reduction in brain lesion num-
ber and volume, as assessed by MRI, over 2 years of delayed-release DMF treatment.
Neurology® 2015;84:1145–1152
GLOSSARY
ANCOVA5 analysis of covariance; BID5 twice daily;CI5 confidence interval;CONFIRM5 Comparator and an Oral Fumarate in
Relapsing-Remitting Multiple Sclerosis; DEFINE 5 Determination of the Efficacy and Safety of Oral Fumarate in Relapsing-
Remitting Multiple Sclerosis; DMF 5 delayed-release dimethyl fumarate (also known as gastro-resistant dimethyl fumarate);
EDSS 5 Expanded Disability Status Scale; GA 5 glatiramer acetate; Gd1 5 gadolinium-enhancing; ITT 5 intent-to-treat; MS 5
multiple sclerosis;MTR5magnetization transfer ratio;Nrf25 nuclear factor (erythroid-derived2)–like 2;PBVC5 percentage brain
volume change; RRMS 5 relapsing-remitting multiple sclerosis; SIENA 5 structural image evaluation using normalization of atro-
phy; SIENAX 5 structural image evaluation using normalization of atrophy cross-sectional; TID 5 3 times daily.
Multiple sclerosis (MS) is a chronic disease of the CNS, characterized by inflammatory demyelination
and axonal degeneration, producing focal lesions of white and gray matter. Much of the damage in
MS is thought to be caused by inflammation and associated oxidative stress; treatments that improve
cellular resistance to inflammatory insults may broaden available options in MS therapy.
Oral delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) has
demonstrated anti-inflammatory and cytoprotective effects mediated via both the nuclear factor
(erythroid-derived 2)–like 2 (Nrf2) pathway and Nrf2-independent pathways in preclinical
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studies.1–4 Two randomized, double-blind, phase
3 studies, Determination of the Efficacy and
Safety of Oral Fumarate in Relapsing-Remitting
Multiple Sclerosis (DEFINE) and Comparator
and an Oral Fumarate in Relapsing-Remitting
Multiple Sclerosis (CONFIRM), were con-
ducted among patients with relapsing-remitting
MS (RRMS).5,6 In both studies, DMF treatment
produced significant clinical and neuroradiologic
benefits over 2 years, including reductions in re-
lapses, new lesion counts, and lesion volumes
assessed by MRI, with an acceptable safety
profile.
DMF is approved in the United States for the
treatment of relapsing forms of MS.7 Here, we
report the effects of DMF on MRI brain lesions
observed in CONFIRM. Tertiary analyses were
also conducted to assess changes in brain volume
(atrophy) and in magnetization transfer ratio
(MTR), a quantitative MRI technique used to
detect changes in intrinsic tissue structure,
including myelin content, in the CNS.8–10
METHODS Standard protocol approvals, registrations, and
patient consents. The CONFIRM study (ClinicalTrials.gov
identifier NCT00451451) was approved by central and local ethics
committees and performed in accordance with The International
Conference on Harmonisation Guidelines on Good Clinical
Practice11 and the ethical principles outlined in the Declaration of
Helsinki.12 Written informed consent was obtained from all patients
before evaluations were performed to determine eligibility.
Study design. CONFIRM was a 2-year, phase 3, randomized,
international, multicenter, parallel-group, placebo-controlled study,
with active reference comparator, that evaluated the safety and
efficacy of DMF in patients with RRMS, as reported previously.6
Patients from 200 sites in 28 countries were randomized 1:1:1:1 to
receive PO placebo, PO DMF 240 mg twice daily (BID), PO DMF
240 mg 3 times daily (TID), or glatiramer acetate (GA) 20 mg once
daily by subcutaneous injection for 96 weeks. DMF and placebo
treatments were double-blind, while GA treatment was rater-blind.
MRI secondary and tertiary outcomes of the study were assessed in
a subset of patients at centers with appropriate imaging facilities. These
included the number of new or enlarging T2-hyperintense, new non-
enhancing T1-hypointense, and gadolinium-enhancing (Gd1) le-
sions; volume of T2-hyperintense, nonenhancing T1-hypointense,
and Gd1 lesions; percentage brain volume change (PBVC); and per-
centage change in whole brain MTR.
Patients. As reported previously,6 patients aged 18–55 years
with a confirmed diagnosis of RRMS according to McDonald
criteria 200513 and an Expanded Disability Status Scale (EDSS)
score of 0–5.0 were enrolled in the MRI portion of the trial at
screening, prior to randomization (figure 1). Additional eligibility
criteria are included in e-Methods on the Neurology® Web site at
Neurology.org.
MRI assessments. MRI scans were obtained at baseline and at
weeks 24, 48, and 96 in patients from a subset of sites with full
MRI capabilities. Approximately 95% of patients at these sites
chose to participate. Original MRI scans from each site were evaluated
in a blinded manner by qualified personnel at a central reading facility
(University College London Institute of Neurology, UK).
Lesion volumes (T2-weighted and nonenhancing T1-weighted)
were assessed at baseline and weeks 48 and 96, and numbers
of new or enlarging T2-weighted lesions and new nonenhancing
T1-weighted lesions were assessed at weeks 48 and 96. Gd1 lesion
count and volume were assessed at baseline and weeks 24, 48, and 96.
Lesion assessment methodology is provided in e-Methods.
Normalized brain volume was assessed at baseline and week 24
using the structural image evaluation using normalization of atrophy
(SIENA) cross-sectional (SIENAX) method, and PBVC was as-
sessed at each post-baseline MRI visit relative to earlier measure-
ments by the SIENA method.14 A more stringent post hoc
quality assessment and analysis of PBVC is also included (metho-
dology described in e-Methods). MTR analysis was conducted
using a purposefully developed pipeline (methodology described
in e-Methods). Median whole brain MTR at baseline, week 48,
and week 96 was reported.
Statistical analyses. The intent-to-treat (ITT) population
comprised all randomized patients who received at least one
dose of study treatment. The MRI cohort comprised ITT
patients who consented to participate in the MRI portion of
the study and had any MRI data.
A negative binomial regression model was used to analyze the
total number of new or enlarging T2-hyperintense lesions and the
number of new T1-hypointense lesions at 2 years (secondary end-
points) and 1 year (tertiary endpoints). The model was adjusted
for region (defined by type of health care system, access to health
care, and geography) and baseline lesion volume (T1-hypointense
or T2-hyperintense). The number of Gd1 lesions at 1 and 2 years
(tertiary endpoints) were analyzed using an ordinal logistic regression
model, adjusted for region and baseline Gd1 lesion number.
Analysis of covariance (ANCOVA) on ranked data was used
to assess the effects of treatment on volume of T1-hypointense,
T2-hyperintense, and Gd1 lesions at 1 and 2 years (tertiary
endpoints). The model included treatment group and adjust-
ments for region and baseline lesion volume (T1-hypointense,
T2-hyperintense, or Gd1).
ANCOVA of ranked data was used to assess the effects of treat-
ment on PBVC at 2 years, relative to baseline and relative to week
24. The model included treatment group and adjustments for region
and brain volume at reference visit (baseline or week 24).
ANCOVA was also used to assess the effects of treatment on
the percentage change from baseline of whole brain MTR at
1 and 2 years. The model included treatment group and adjust-
ments for region and baseline MTR value.
Linear relationships between MRI endpoints and clinical end-
points were calculated using Spearman rank correlation coefficients.
Classification of evidence. This study provides Class I evi-
dence of reduction in brain lesion number and volume, as as-
sessed by MRI, over 2 years of treatment with DMF 240 mg
BID or TID, compared with placebo, in patients with RRMS.
DMF BID and TID reduced the mean number of new or enlarg-
ing T2-hyperintense lesions by 71% and 73%, respectively, the
mean number of new nonenhancing T1-hypointense lesions by
57% and 65%, and Gd1 lesions by 74% and 65% (reductions
in the odds of having more lesions) over 2 years vs placebo (all
p , 0.001). Lesion volumes were also significantly reduced.
RESULTS Patients. Of the 1,430 patients random-
ized, 1,417 were included in the ITT population,
and 681 patients in the MRI cohort (figure 1). Baseline
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demographic and disease characteristics of the MRI
cohortwere comparable among treatment groups (table 1)
and with the non-MRI cohort (tables e-1 and e-2).
Lesion number. Compared with placebo, DMF BID
and TID reduced the mean number of new or enlarg-
ing T2-hyperintense lesions that developed over 2 years
by 71% and 73%, respectively (both p , 0.0001)
(figure 2A and table e-3). This robust effect was
evident at 1 year and was maintained at 2 years. DMF
reduced the number of new or enlarging T2-hyperintense
lesions by 67% (BID) and 70% (TID) during the first
year, and by 76% (both groups) during the second year
(all p, 0.0001). In the GA group, the relative reduction
in mean T2-hyperintense lesion number vs placebo was
54% over 2 years: 52% in the first year and 57% in the
second year (all p , 0.0001).
Compared with placebo, DMF reduced the mean
number of new nonenhancing T1-hypointense le-
sions that developed over 2 years by 57% (BID)
and 65% (TID) (p , 0.0001 for both comparisons),
with respective relative reductions of 41% (p5 0.0030)
and 60% (p , 0.0001) in the first year, and 70% and
71% (both p , 0.0001) in the second year (figure 2B
and table e-4). Relative to placebo, GA reduced the
mean new nonenhancing T1-hypointense lesion num-
ber by 41% (p5 0.0021) over the 2 years: 30% in the
first year and 55% in the second year (p5 0.0402 and
0.0002, respectively).
DMF also reduced Gd1 lesions at 6 months, with
relative reductions over placebo of 81% (BID) and
69% (TID) (reductions in the odds of having more
lesions; p , 0.0001 for both comparisons); the rela-
tive reduction with GA at this time point was 42%
(p5 0.0201) (figure 2C and table e-5). Relative odds
reductions over placebo in Gd1 lesions were 87%
(BID), 77% (TID), and 63% (GA) (all p , 0.0001)
at 1 year and 74% (BID, p , 0.0001), 65% (TID,
p 5 0.0001), and 61% (GA, p 5 0.0003) at 2 years.
Figure 1 Patient flow
Final intent-to-treat population of patients whowere enrolled in theMRI cohort and then randomized and received at least 1 dose of study treatment was n5
681. AE 5 adverse event; DMF 5 delayed-release dimethyl fumarate (also known as gastro-resistant DMF); GA 5 glatiramer acetate; MS 5 multiple
sclerosis; QD 5 once daily; SC 5 subcutaneous.
Neurology 84 March 17, 2015 1147
ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
The robustness of these findings was confirmed by
sensitivity analyses based on all observed data, and on
observed data prior to starting alternative MS medica-
tion (figure e-1). These sensitivity analyses indicated
that neither the data imputation method used in
the primary analysis nor the exclusion of data after pa-
tients switched to alternative MS medication affected
the results.
Although this study was not designed to assess supe-
riority or noninferiority of DMF over GA, the reduc-
tions in lesion numbers over 2 years relative to
placebo were numerically greater in both DMF dose
groups than in the GA group. Direct comparisons (post
hoc) of the relative effect of BID and TID vs GA pro-
duced rate ratios (95% confidence intervals [CI]) of
0.64 (0.46, 0.88) and 0.59 (0.43, 0.82) for new/enlarg-
ing T2-hyperintense lesions (nominal p values for the
comparison: p 5 0.0068 and p 5 0.0017), and 0.74
(0.52, 1.04) and 0.59 (0.41, 0.84) for new nonenhanc-
ing T1-hypointense lesions (nominal p 5 0.0846 and
p 5 0.0033), respectively. Odds ratios (95% CI) for
Gd1 lesions were 0.71 (0.40, 1.25) for BID and 0.87
(0.50, 1.52) TID vs GA (not significant).
Lesion volume. A reduction in T2-hyperintense lesion
volume was seen within the first year of DMF
treatment, and was maintained throughout the study.
Lesion volume increased in the placebo group, with
mean 6 SD change from baseline to 2 years of
744.7 6 3,662.4 mm3, representing a median
15% increase from baseline, vs a reduction in T2-
hyperintense lesion volume by 1,035.8 6 2,657.2,
800.5 6 3,933.3, and 946.0 6 3,766.6 mm3 (median
percentage change27%,22%, and26%) in the BID,
TID, and GA groups, respectively (p , 0.0001 for all
comparisons vs placebo) (figure 2D and table e-3).
Increases in nonenhancing T1-hypointense lesion
volume at 2 years were attenuated with DMF treatment
relative to placebo, with mean6 SD changes from base-
line of 198.1 6 1,380.0 (BID) and 190.7 6 1,204.2
(TID), vs 342.4 6 878.5 mm3 with placebo (median
percentage change 11% and 9% vs 20%; p 5 0.0005
and p5 0.0015 vs placebo), respectively (figure 2E and
table e-4). Treatment with GA also attenuated the
increase in T1-hypointense lesion volume at 2 years rel-
ative to placebo, with mean6 SD change from baseline
of 214.7 6 1,389.0 mm3 (median percentage change
9%, p 5 0.0013 vs placebo).
Compared with placebo, DMF reduced Gd1 lesion
volumes, with mean6 SD values at 2 years of 35.96
128.5 (BID) and 42.66 149.9 mm3 (TID), compared
with 141.86 339.1 mm3 for placebo (post hoc analysis;
both p , 0.0001 vs placebo) (figure 2F and table e-5).
This treatment effect was apparent within 6 months.
The mean 6 SD reduction from baseline to 2 years
in Gd1 lesion volume was 251.8 6 595.6 (BID) and
Table 1 Key baseline demographics and disease characteristics for the MRI cohort
Characteristics Placebo (n 5 167) DMF BID (n 5 169) DMF TID (n 5 170) GA (n 5 175)
Age, y, mean (SD) 36.6 (9.1) 38.5 (8.9) 38.2 (9.7) 36.8 (8.8)
Female, n (%) 116 (69) 118 (70) 121 (71) 123 (70)
McDonald criteria, n (%) patients
1 criterion 142 (85) 139 (82) 147 (86) 150 (86)
2–4 criteria 25 (15) 30 (18) 23 (14) 25 (14)
Prior approved MS treatment, n (%)a 48 (29) 47 (28) 49 (29) 51 (29)
Relapses in previous year, mean (SD) 1.3 (0.6) 1.3 (0.7) 1.3 (0.7) 1.3 (0.7)
EDSS score at baseline, mean (SD)b 2.5 (1.1) 2.5 (1.1) 2.5 (1.2) 2.5 (1.3)
T2 lesion volume, mean (SD) mm3 14,595 (13,267) 13,876 (13,348) 12,827 (13,385) 13,789 (13,562)
Median 10,822 9,701 7,767 9,435
T1-hypointense lesion volume, mm3, mean (SD) 3,722 (5,262) 3,594 (5,181) 3,135 (4,606) 3,338 (4,729)
Median 1,763 1,473 1,368 1,344
Number of Gd1 lesions,c mean (SD) 2.7 (7.7) 2.7 (6.2) 1.9 (5.0) 2.4 (6.8)
Patients with Gd1 lesions, n (%) 79 (47) 82 (49) 70 (41) 78 (45)
Normalized whole brain volume, mean (SD) cm3 1,496 (93) 1,498 (98) 1,487 (103) 1,484 (138)
Abbreviations: DMF5 delayed-release dimethyl fumarate (also known as gastro-resistant DMF); EDSS5 Expanded Disability Status Scale; GA5 glatiramer
acetate; Gd1 5 gadolinium-enhancing; MS 5 multiple sclerosis.
a Interferon b-1a (20%), interferon b-1b (11%), natalizumab (1%), and GA (,1%), all balanced across groups; one patient was randomized to GA who had
previously been exposed to GA. Patients may have received more than one prior MS medication. Patients may also have received other nonapproved
therapies for MS (the proportion of patients in the MRI cohort receiving any MS medication prior to study was 28%–29% across treatment groups).
b Score on the EDSS scale, which ranges from 0 to 10, with higher scores indicating greater degree of disability.
c From T1-weighted scans.
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181.7 6 738.5 mm3 (TID), compared with 7.2 6
448.6 mm3 (placebo), and the median percentage
change from baseline was 2100% (BID) and 2100%
(TID) (both p, 0.0001 vs placebo,114%) (table e-5).
In patients treated with GA, Gd1 lesion volume was
45.6 6 135.8 mm3 at 2 years (post hoc analysis; p ,
0.0001 vs placebo) and was reduced from baseline to 2
years by 202.5 6 573.5 mm3 (median percentage
change from baseline2100%, p, 0.0001 vs placebo).
Brain atrophy and whole brain MTR. Median PBVC
from baseline to 2 years was less than 1% in the
placebo group as well as the active treatment groups
(figure 3), indicating a relatively low average rate of
Figure 2 Lesion number (A–C) and volume (D–F) of T2 lesions, T1-hypointense lesions, and Gd1 lesions over time
Patient numbers refer to those who provided data both at baseline and at each scheduledMRI analysis. Relative reductions (vs placebo) in the risk of having a
greater number of gadolinium-enhancing (Gd1) lesions were based on the odds ratio from the prespecified analysis model of ordinal logistic regression
(a conservative method, chosen to minimize undue influence of outlier Gd1 lesion counts on the estimated treatment effect), for categories of patients with
0, 1, 2, 3–4, and $5 lesions. Comparisons vs placebo were based on anegative binomial regression, adjusted for region and baseline lesion volume; bordinal
regression, adjusted for region and baseline lesion number; and canalysis of covariance on ranked data, adjusted for region and baseline lesion volume. dThe
comparison vs placebo of mean Gd1 lesion volume at postbaseline timepoints was a post hoc analysis (change from baseline was the prespecified analysis).
ep, 0.0001; fp, 0.01; gp,0.05; hp,0.001 for comparison vs placebo. CI5 confidence interval; DMF5 delayed-release dimethyl fumarate (also known as
gastro-resistant DMF); GA 5 glatiramer acetate.
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atrophy during the study. Data from baseline to week
24 showed no evidence of pseudoatrophy in active
treatment arms (table e-6). At 2 years, PBVC favored
DMF, but not GA, relative to placebo, although none
of the changes reached statistical significance: the
median decrease in PBVC was 30% (BID; p 5
0.0645) and 21% (TID; p 5 0.2636) relative to pla-
cebo, vs a median relative increase of 2% for GA vs
placebo (p 5 0.8802). Between years 1 and 2, there
was a 32% reduction in atrophy with DMF relative to
placebo (p 5 0.0359 [BID] and p 5 0.0755 [TID]),
and 28.8% reduction in the GA group (p 5
0.0805), based on median PBVC values. Similar
results were obtained in the more stringent post
hoc quality assurance reanalysis of PBVC (table
e-7). At 2 years, mean (median) percentage changes
in MTR from baseline were20.167 (0.000),20.008
(0.000), and 10.010 (0.000) for DMF BID, TID,
and GA groups, respectively, compared with 20.419
(20.323) for placebo (table e-8); none of the relative
changes in MTR reached statistical significance com-
pared with placebo.
Subgroup analysis. Compared with placebo, DMF
(BID or TID) was associated with robust reductions in
numbers of new/enlarging T2-hyperintense lesions and
Gd1 lesions across a range of prespecified patient
subpopulations stratified by baseline characteristics (sex,
age ,40 vs $40 years, #1 vs $2 relapses in the year
prior to study, McDonald criteria, prior MS treatment
status, EDSS score, T2 lesion volume, and Gd1 lesion
status) (figure e-2).
Clinical–MRI correlations. In the overall cohort after 2
years, there were significant correlations of change in
T2 and T1 lesion load and in new lesion counts with
relapse rate, and no significant correlation of PBVC
(tertiary endpoint) with change in EDSS (table e-9).
DISCUSSION MRI is an important tool for monitoring
disease activity and is widely used in clinical trials of MS
therapies. In this study, we have shown that DMF signif-
icantly reduced disease activity as measured by MRI
active lesion number (an indicator of recent inflammation
that correlates with relapse rates)15,16 and disease progres-
sion, as measured by total lesion volume (an indicator of
overall disease burden),17 compared with placebo. These
effects were evident at the first MRI assessment for
T2-hyperintense lesions and Gd1 lesions (1 year and
6 months, respectively) and persisted over the 2-year
evaluation period. Furthermore, these findings were
accompanied by reductions in new nonenhancing
T1-hypointense lesions relative to placebo, which may
suggest an effect of DMF in reducing tissue damage
since persistent T1-hypointense lesions are known to
correlate with axonal loss.18
The MRI lesion outcomes observed in CONFIRM
are consistent with the robust benefits reported in the
phase 3 DEFINE study5 and the phase 2 clinical study
with DMF.19–21 Although interpretation of comparisons
between studies is limited by many considerations,
including differences in study design, populations, end-
points, and standards of care at the time of study con-
duct, theseMRI lesion outcomes for patients treated with
DMF are generally comparable with those reported in
other phase 3 studies of investigational and marketed oral
MS therapies.5,22–25 The MRI findings observed with
DMF also compare favorably with the MRI lesion out-
comes seen in the GA arm of this trial, reinforcing the
findings of indirect comparison of clinical outcomes of
this study that have been reported elsewhere.6
Figure 3 Effect of treatment on brain atrophy
Measured using the structural image evaluation, using normalization, of atrophy method. *DMF 5 delayed-release DMF (also known as gastro-resistant
DMF); GA 5 glatiramer acetate.
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The MRI outcomes in CONFIRM and other clini-
cal studies are consistent with preclinical data,2,4,26 sug-
gesting that anti-inflammatory properties may
contribute to the efficacy of DMF in RRMS. This is
illustrated by the significant reductions in new or
enlarging T2-hyperintense, new T1-hypointense,
and Gd1 lesion counts, and total lesion volume.
The MRI benefits of DMF are observed across patient
subgroups differing in baseline disease activity and
demographic characteristics (despite limited patient
numbers), further supporting the potential value of
this treatment across a broad spectrum of patients
with RRMS.
MTR has not been explored previously in a large
phase 3 study and, therefore, investigation of MTR
in the present study and companion phase 3 study,
DEFINE, represents a novel approach to obtain explor-
atory information and guide future study design. Brain
atrophy data were also collected for tertiary analysis. Sta-
tistically significant treatment effects of DMF on MTR
outcomes (both doses) and brain atrophy (BID only)
were observed in DEFINE.27,28 However, MTR out-
comes and brain atrophy results with DMF did not
reach statistical significance in CONFIRM. The rate
of atrophy in the placebo arm during the CONFIRM
study was lower in comparison with the placebo arms of
other phase 3 studies of oral MS therapies.22,24 In addi-
tion, there was no increase in brain volume loss with
DMF during the first 24 weeks, indicating no signifi-
cant pseudoatrophy effect due to a decrease in inflam-
matory tissue and edema.
Neither of the phase 3 studies was prospectively pow-
ered to detect a treatment effect on brain atrophy and
MTR. Assessments of these parameters were performed
in the MRI cohort that was about half the size of the
whole trial population. The relatively small changes in
MTR and atrophy measures in all study arms, including
placebo, combined with the smaller sample size, may
have reduced the sensitivity to detect a significant thera-
peutic effect over 2 years. A delayed onset of effect may
also be relevant, as suggested by more evident reductions
in PBVC in the DMF arms during the second year.
Previous trials of GA in clinically isolated syn-
dromes29 and RRMS30 revealed 28% less brain atro-
phy and no difference in brain volume change after a
mean follow-up of 3.8 years and 18 months, respec-
tively. Although we did not observe less PBVC over 2
years in the GA-treated arm vs placebo, there was a
trend for less atrophy in the second year.
Overall, the CONFIRM imaging data are consistent
with DMF having robust anti-inflammatory effects. The
positive imaging findings, when considered alongside
clinical relapse and disability data, as well as the accept-
able tolerability and safety profile of this agent,5,6 support
the use of DMF as a valuable new treatment option in
RRMS.
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